Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Sep 15

PMID 28906427

Citations 41

Authors

Vera Loizzi

Vittoria Del Vecchio

Giulio Gargano

Maria De Liso

Anila Kardashi

Emanuele Naglieri

Leonardo Resta

Ettore Cicinelli

Gennaro Cormio

Affiliations

Soon will be listed here.

Abstract

The creation of new blood vessels from existing ones, which is a mechanism called "angiogenesis", is essential in cancer to supply cancerous growth. Moreover, the development and the progression of the tumor and its metastases are the result of an efficient vascular response. Cancer cells release and activate different angiogenic growth factors and their receptors in the tumor microenvironment to promote the angiogenic process. The most important pro-angiogenic factor is the "Vascular Endothelial Growth Factor" (VEGF) because of its mitogen activity on vascular endothelium. Bevacizumab is a monoclonal antibody that obstructs the binding of circulating vascular endothelial growth factor to its receptors and has been approved for the treatment of primary and recurrent ovarian cancer but also for many other solid tumors.

Citing Articles

NF-κB pathway and angiogenesis: insights into colorectal cancer development and therapeutic targets.

Bahrami A, Khalaji A, Najafi M, Sadati S, Raisi A, Abolhassani A Eur J Med Res. 2024; 29(1):610.

PMID: 39702532 PMC: 11658081. DOI: 10.1186/s40001-024-02168-w.

Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination.

Fujimoto H, Yoshihara M, Rodgers R, Iyoshi S, Mogi K, Miyamoto E Cancer Metastasis Rev. 2024; 43(3):1037-1053.

PMID: 38546906 PMC: 11300578. DOI: 10.1007/s10555-024-10169-8.

Angio-Long Noncoding RNA MALAT1 (rs3200401) and MIAT (rs1061540) Gene Variants in Ovarian Cancer.

Fawzy M, Ibrahiem A, Osman D, Almars A, Alshammari M, Almazyad L Epigenomes. 2024; 8(1).

PMID: 38390896 PMC: 10885055. DOI: 10.3390/epigenomes8010005.

Proteomic analysis of small extracellular vesicles unique to cervical cancer.

Molika P, Leetanaporn K, Rungkamoltip P, Roytrakul S, Hanprasertpong J, Navakanitworakul R Transl Cancer Res. 2023; 12(11):3113-3128.

PMID: 38130315 PMC: 10731333. DOI: 10.21037/tcr-23-517.

Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics.

Senrung A, Tripathi T, Aggarwal N, Janjua D, Yadav J, Chaudhary A Curr Top Med Chem. 2023; 24(4):259-300.

PMID: 37867279 DOI: 10.2174/0115680266264349231016094456.

References

Ranieri G, Patruno R, Lionetti A, Di Summa A, Mattioli E, Bufo P . Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma. 2005; 46(11):1639-43. DOI: 10.1080/10428190500205150. View

Gerber H, Ferrara N . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005; 65(3):671-80. View

Ranieri G, Passantino L, Patruno R, Passantino G, Jirillo F, Catino A . The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep. 2003; 10(5):1189-93. View

Hudson L, Zeineldin R, Silberberg M, Stack M . Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res. 2009; 149:203-26. PMC: 3701255. DOI: 10.1007/978-0-387-98094-2_10. View

Brunckhorst M, Xu Y, Lu R, Yu Q . Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment. Am J Pathol. 2014; 184(8):2285-96. PMC: 4116697. DOI: 10.1016/j.ajpath.2014.05.006. View

Le Page C, Puiffe M, Meunier L, Zietarska M, de Ladurantaye M, Tonin P . BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res. 2009; 2:4. PMC: 2674440. DOI: 10.1186/1757-2215-2-4. View

Holmgren L, OReilly M, Folkman J . Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995; 1(2):149-53. DOI: 10.1038/nm0295-149. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Coleman R, Brady M, Herzog T, Sabbatini P, Armstrong D, Walker J . Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18(6):779-791. PMC: 5715461. DOI: 10.1016/S1470-2045(17)30279-6. View

10.

Han E, Monk B . What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol. 2007; 105(1):3-6. DOI: 10.1016/j.ygyno.2007.01.038. View

11.

Bolis G, Scarfone G, Giardina G, Villa A, Mangili G, Melpignano M . Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001; 81(1):3-9. DOI: 10.1006/gyno.2001.6151. View

12.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

13.

Chereau E, Lambaudie E, Houvenaeghel G . Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. Int J Gynecol Cancer. 2013; 23(7):1326-30. DOI: 10.1097/IGC.0b013e31829dc923. View

14.

Presta L, Chen H, OConnor S, Chisholm V, Meng Y, Krummen L . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20):4593-9. View

15.

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave A . Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24(29):4699-707. DOI: 10.1200/JCO.2006.06.0913. View

16.

Ferrara N . Vascular endothelial growth factor. Eur J Cancer. 1996; 32A(14):2413-22. DOI: 10.1016/s0959-8049(96)00387-5. View

17.

Demoulin J, Essaghir A . PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 2014; 25(3):273-83. DOI: 10.1016/j.cytogfr.2014.03.003. View

18.

Sasaki T, Hiroki K, Yamashita Y . The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed Res Int. 2013; 2013:546318. PMC: 3748428. DOI: 10.1155/2013/546318. View

19.

Conteduca V, Kopf B, Burgio S, Bianchi E, Amadori D, De Giorgi U . The emerging role of anti-angiogenic therapy in ovarian cancer (review). Int J Oncol. 2014; 44(5):1417-24. DOI: 10.3892/ijo.2014.2334. View

20.

Dome B, Hendrix M, Paku S, Tovari J, Timar J . Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol. 2007; 170(1):1-15. PMC: 1762709. DOI: 10.2353/ajpath.2007.060302. View